

17 February 2012

Proposal to amend the listing relating to Ranbaxy-Cefaclor 250 mg capsules

PHARMAC is seeking feedback on a proposal to amend the listing relating to Ranbaxy-Cefaclor 250mg capsules through a provisional agreement with Douglas Pharmaceuticals Ltd.

In summary, this proposal would result in Ranbaxy-Cefaclor 250 mg capsules remaining listed in Section B of the Pharmaceutical Schedule and being listed in Section H of the Pharmaceutical Schedule from 1 April 2012 at a price and subsidy of \$24.57 per 100 capsules.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Friday, 2 March 2012** to:

Greg Williams
 Therapeutic Group Manager
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email: Greg.Williams@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Acting Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposal

- Ranbaxy-Cefaclor would remain listed in Section B of the Pharmaceutical Schedule and be listed in Part II of Section H of the Pharmaceutical Schedule at the following price and subsidy (ex-manufacturer and ex-GST) :

Chemical	Presentation	Brand	Pack size	List Price and subsidy
Cefaclor monohydrate	Cap 250 mg	Ranbaxy-Cefaclor	100	\$24.57

- Ranbaxy-Cefaclor would have subsidy and delisting protection until 30 June 2013.

Background

In July 2010 PHARMAC notified that Sandoz Pty Ltd had been awarded Sole Supply for Cefaclor Sandoz 250 mg capsules from 1 May 2011 until 30 June 2013 for both the Hospital and Community markets. Subsequent to this announcement there have been several delays to the implementation of sole supply for Cefaclor-Sandoz due to stock not being available for

the market. In February 2012 PHARMAC and Sandoz reached agreement to withdraw the sole supply status for Cefaclor-Sandoz due to concerns regarding ongoing supply.

Douglas Pharmaceuticals Ltd has supplied Ranbaxy-Cefaclor 250 mg capsules since 1 October 2004. Douglas and PHARMAC have reached a provisional agreement for ongoing listing for Ranbaxy-Cefaclor 250 mg capsules.

Ranbaxy-Cefaclor has remained listed throughout this period as Douglas have been able to source a limited amount of stock. However, there may be stock shortages for the next six months, and we ask pharmacists to remain patient with supply during this period if stock is not available. PHARMAC will alert pharmacists when stock is not available to allow this information to be provided to prescribers to allow them time to prescribe alternative products.

Please note that the cefaclor suspension may be dispensed with endorsement if there are no cefaclor caps available.